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ABSTRACT
The optimal form of treatment for children with relapsed or refractory acute promyelocytic leukemia (APL) is
unclear. We retrospectively analyzed the results of 32 (11 autologous, 21 allogeneic) hematopoietic stem cell
transplants (HSCT) performed for children originally treated on either the Eastern Cooperative Group
E2491 Trial or the Cancer and Leukemia Group B C9710 Trial and subsequently diagnosed with relapsed or
refractory APL. For autologous HSCT, the incidence of treatment-related mortality (TRM) and relapse was
0% (95% confidence interval [CI], 0%-30%) and 27% (95% CI, 9%-57%), respectively. The 5-year event-free
survival (EFS) and overall survival (OS) following autologous HSCT was 73% (95% CI, 43%-91%) and 82%
(95% CI, 51%-96%), respectively. For allogeneic HSCT, the incidence of TRM and relapse was 19% (95%
CI, 7%-41%) and 10% (95% CI, 2%-30%), respectively. The 5-year EFS and OS following allogeneic HSCT
was 71% (95% CI, 50%-86%) and 76% (95% CI, 55%-90%), respectively. There was no significant difference
in EFS or OS between autologous and allogeneic HSCT. This data demonstrates that autologous and allogeneic
HSCT are both effective therapies for treatment of children with relapsed or refractory APL. AutologousHSCT
is associated with a low incidence of TRM, whereas allogeneic HSCT is associated with a low incidence of
relapse, suggesting a strong GVL effect against residual APL.
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In children, acute promyelocytic leukemia (APL) is
a rare subtype of acute myelogenous leukemia (AML),
accounting for only 4% to 8% of AML in the USA [1].
All cases are associated with an abnormal fusion of the
retinoic acid receptor (RAR)-a gene on chromosome
17, usually to the promyelocytic (PML) gene on chro-
mosome 15 [1]. Since the introduction of all-trans ret-
inoic acid (ATRA) combined with conventional
therapy, the disease-free survival (DFS) of children
with newly diagnosed APL now approaches 75% [2-6].824For those patients with relapsed APL, occasional
patients have demonstrated second remissions for as
long as 8 years following treatment with chemotherapy
and/or ATRA [7-10]. However, most patients ulti-
mately undergo consolidative autologous [10-14], allo-
geneic [10-13,15,16], or haploidentical hematopoietic
stem cell transplantation (HSCT) [17]. The majority
of reports on the use of HSCT for treatment of relapsed
or refractory APL deal primarily with adult patients,
making the benefit of these therapies for children
unclear. Here, we report the outcomes in 32 children
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(ECOG) E2491 Trial [6,18,19] or the Cancer and Leu-
kemia Group B (CALGB) C9710 Trial [20] from 1992
to 2005 who underwent any form of HSCT for treat-
ment of relapsed or refractory APL.
PATIENTS AND METHODS
Approval for the study was obtained by the ECOG
and CALGB Executive Review Committees. The 32
patients included on this study were diagnosed with
APL according to bone marrow morphology [19]. Cy-
togenetic analysis and/or reverse-transcriptase poly-
merase chain reaction (RT-PCR) confirmed the
presence of t(15;17) in all cases.
Initial Therapy
Between May 1992 and February 1995, 71 of the 350
patients enrolled on the ECOG E2491 trial were chil-
dren (ages 1-18 years). Patients were randomly assigned
to receive induction therapy with either daunorubicin
(45 mg/m2/day for 3 days) plus cytarabine (100 mg/
m2/day for 7 days), or ATRA (45 mg/m2/day until com-
plete remission or 90 days). Two cycles of consolidation
chemotherapy with daunorubicin and cytarabine were
administered, following which patients were randomly
assigned to receive maintenance ATRA for 1 year or
observation. The results of the ECOG E2491 trial
have been previously reported [6,18,19].
Between June 2000 and March 2005, 91 of the 582
patients enrolled on the CALGB C9710 trial were chil-
dren (ages 1-18 years). Patients were treated with
ATRA (45 mg/m2/day from day 1 until achievement
of CR), cytarabine (200 mg/m2/day for 7 days from
day 3 to day 9), and daunorubicin (50 mg/m2 for 4
days; 1.5 mg/kg for 4 days for age\3). Patients were
randomly assigned to either proceed directly to 2 cycles
of consolidation with ATRA plus daunorubicin, or to
first receive 2 cycles of arsenic trioxide (ATO). Patients
were then randomized to receive maintenance therapy
with ATRA alone for 1 year, or ATRA plus 6-mercap-
topurine and methotrexate (MTX) for 1 year. The
results of the CALBG C9710 trial have been prelimi-
narily reported [20].
A total of 52 children (ages 1-18 years at the time
of diagnosis) treated on these 2 trials were reported
to have relapsed or had primary-refractory disease,
defined as failure to achieve CR with the protocol
induction chemotherapy. Six patients are known to
have not undergone HSCT (death during reinduction,
n5 2; refused HSCT and died, n5 2; treated with dif-
ferentiating chemotherapy only, n 5 2). Fourteen pa-
tients were excluded from the analysis because of an
inability to obtain sufficient data on HSCT type and
outcomes from the transplant centers. Characteristics
at the time of diagnosis of the remaining 32 patients
who underwent HSCT are summarized in Table 1.Treatment for Relapsed or Refractory Disease
Multiple treatment regimens were utilized, as
shown in Table 2. Nineteen patients received differen-
tiating therapy alone (ATRA, n 5 8; ATO, n 5 9;
ATRA 1 ATO, n5 2). Eight patients received differ-
entiating agents plus chemotherapy, including dauno-
rubicin, etoposide, idarubicin, and cytarabine, all of
which have been shown to have efficacy against APL
[13,21]. Three patients were treated with only cyto-
toxic chemotherapy regimens, the most common of
which was idarubicin plus cytarabine. The treatment
for 2 patients was unknown. Molecular assessment
of the PML-RARa fusion gene by RT-PCR was not
performed before HSCT in all patients. When RT-
PCR was performed, assay sensitivities varied from
1  1023 to 1  1025.
Hematopoietic Stem Cell Transplant
Eleven patients underwent autologous HSCT and
21 patients underwent allogeneic HSCT. RT-PCR of
the autograft product was negative in 6 patients and
unknown in 5 patients. Multiple different donor types,
conditioning regimens, and graft-versus-host disease
(GVHD) prophylaxis strategies were utilized, as shown
in Table 3. When available, HLA-typing examined
either 8 genetic loci (A-, B-, C-, DR-loci) or 10 (A-,
B-, C-, DR-, DQ-loci). The stem cell source was
known for 16 patients, (bone marrow, n 512;
Table 1. Patient Characteristics at Diagnosis
Total No. of
Patients
Autologous
11
Allogeneic
21
P-
Value
Age at diagnosis,
median (range)
11 years (1-16) 11 years (1-16)
\10 years 5 6 .44
$10 years 6 15
Sex, male/female 5/6 9/12 1
White blood cell count .68
\2000/mL 4 5
2000-9999/mL 4 9
$10,000/mL 3 7
Platelet count .12
\40,000/mL 5 16
$40,000/mL 6 5
Coagulopathy* .69
Yes 6 10
No 3 8
Unknown 2 3
Morphology .63
Classic M3 9 15
Microgranular
variant (M3v)
1 4
Unknown 1 2
Karyotype .4
t(15;17) 7 17
t(15;17) 1 additional
changes
4 4
*Fibrinogen\150 mg/dL
826 C. C. Dvorak et al.peripheral blood stem cells [PBSC], n 5 3; and cord
blood, n51). Thirteen patients received total body ir-
radiation (TBI) as part of the conditioning regimen,
with doses ranging from 1200 to 1375 cGy. The most
commonly employed conditioning regimen utilized
a 2-agent combination of cyclophosphamide (Cy)
with either TBI or busulfan. Most of the other regi-
mens added a third agent (including cytarabine, etopo-
side, or thiotepa) to that backbone. Three patients who
received mismatched transplants had ex vivo T cell de-
pletion for GVHD prophylaxis.
Statistical Analysis
Categoric variables were compared by 2-sided
Fisher’s exact test. Event-free survival (EFS) and over-
all survival (OS) were estimated by the Kaplan-Meier
method using log-rank tests (SPSS 16.0, Chicago,
IL). Events were defined as graft failure, treatment-
related mortality (TRM), or relapse. There were no
secondary malignancies reported.
RESULTS
Patient Characteristics
Diagnosis. As shown in Table 1, 10 patients (32%)
were considered high risk at diagnosis based on
a WBC count .10,000 cells/mL [22]. Other variables,
including the microgranular variant and the addition
Table 2. Patient Characteristics at Relapse
Total No. of
Patients
Autologous
11
Allogeneic
21
P-
Value
Induction therapy .7
E2491 DNM/AC 5 7
E2491 ATRA 0 7
C9710 6 7
Relapse/refractory 10/1 19/2 1
Time to relapse
from CR, median
(range)
11 months
(1-20)
9 months
(4-46)
1
\6 months 2 3
6-12 months 4 8
.12 months 4 8
NA 1 2
EMD at relapse 1
Yes 2 3
No 7 15
Unknown/NA 2 3
Salvage regimen .72
ATRA alone 3 5
ATO alone 2 7
ATRA 1 ATO 1 1
Differentiating agent 1 Chemo 5 3
Chemo only 0 3
Unknown 0 2
ATRA indicates all-trans retinoic acid; DNM/AC, daunomycin and
cytarabine; ATO, arsenic trioxide; Differentiating agent, ATRA
or ATO; CR, complete remission; EMD, extramedullary disease;
NA, not applicable.of chromosomal abnormalities, were present in a small
number of patients. There were no significant differ-
ences in presenting characteristics between patients
who underwent autologous versus allogeneic HSCT.
Relapse
As shown in Table 2, three patients failed to achieve
CR with their initial protocol induction therapy and
underwent HSCT for treatment of primary-refractory
disease. The other 29 patients underwent HSCT for
treatment of relapse, which occurred at a median of
10 months (range: 1-46 months) from time of first re-
mission, with 41% of relapses occurring later than 12
months from time of first remission. All relapses
occurred in the bone marrow. Four patients also had
evidence of a concomitant extramedullary relapse (ce-
rebrospinal fluid, n 5 2; skin, n 5 2). All patients
achieved morphologic CR prior to HSCT. Sixteen pa-
tients were known to have had RT-PCR analysis for
PML-RARa prior to HSCT, 2 of whom were positive
(assay sensitivity5 1 1023 for 1 patient, 1 1024 for
the other). There were no significant differences in
Table 3. Patient Characteristics at Time of Transplant
Total No. of Patients Autologous 11 Allogeneic 21 P-Value
Age at transplant,
median (range)
12 years
(2-18)
13 years
(2-18)
\10 years 4 5 .68
$10 years 7 16
Time from CR to transplant .33
\3 months 5 15
$3 months 3 3
Unknown 3 3
Molecular remission 1
Yes 6 8
No 1 1
Unknown 4 12
Donor NA
Matched related NA 9
Mismatched related NA 3
Matched unrelated NA 5
Mismatched unrelated NA 4
Conditioning .02
TBI/CY 1 5
TBI/CY/other 0 7
BU/CY 6 4
BU/CY/other 1 4
Other 2 0
Unknown 1 1
GVHD Prophylaxis NA
CSA or FK only NA 3
CSA or FK 1 MTX NA 9
CSA or FK 1 steroids NA 4
T cell depletion NA 3
Unknown NA 2
CR indicates complete remission; TBI, total body irradiation; Cy,
cyclophosphamide; Bu, busulfan; GVHD, graft-versus-host dis-
ease; CsA, cyclosporine; FK, tacrolimus; MTX, methotrexate;
NA, not applicable.
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went autologous versus allogeneic HSCT.
Transplant
Patient characteristics at time of HSCT are shown
in Table 3. Patients undergoing allogeneic HSCT
were more likely to have received a TBI-based condi-
tioning regimen (P5 .02). Statistical analysis (data not
shown) did not reveal a significant impact of age at
time of transplant, time from achievement of CR to
HSCT, type of allogeneic donor, type of conditioning
regimen, or type of GVHD prophylaxis upon any of
the endpoints (TRM, relapse, EFS, or OS).
Transplantation Outcomes
Engraftment and TRM. Engraftment data was
available on all patients. All but 2 patients achieved
primary neutrophil engraftment (94%; 95% CI,
79%-99%). One patient died prior to neutrophil en-
graftment on day111 postallogeneic HSCT secondary
to necrotizing tracheobronchitis. One patient who
received a bone marrow transplant from a matched
related donor (MRD) showed no evidence of WBC
recovery on day 128 and was determined to have pri-
mary graft failure. A second infusion of peripheral
blood stem cells from the same donor was performed
with successful engraftment, but the patient died on
day 1469 secondary to complications of chronic
GVHD (cGVHD). Including the 2 patients above,
a total of 4 patients (13%; 95% CI, 4%-29%) died
of transplant-related causes between days 111 and
1497 after HSCT. The other causes of TRM were
idiopathic pneumonia syndrome, and posttransplanta-
tion lymphoproliferative disease. All patients experi-
encing TRM had received allogeneic transplants
(MRD, n 5 2; partially matched related donor, n 5 1;
and matched unrelated donor, n 5 1). Therefore, the
3-year cumulative incidence of TRM following autolo-
gous HSCT was 0% (95% CI, 0%-30%) and the 3-year
cumulative incidence of TRM following allogeneic
HSCT was 19% (95% CI, 7%-41%). Statistical analy-
sis (data not shown) did not show any factors signifi-
cantly associated with an impact upon TRM, though
all treatment-related deaths took place early in the
study period, with none occurring after 1996.
GVHD
Information on GVHD was available for 16 of the
19 patients who engrafted following allogeneic HSCT,
including 8 recipients of related-donor transplants and
8 unrelated-donor transplants. Five of the 16 patients
(31%; 95% CI, 14%-56%) developed grade II-IV
acute GVHD (aGVHD) (MRD graft, n5 2; unrelated
donor graft, n5 3). Two of the 16 patients (13%; 95%
CI, 2%-37%) developed extensive cGVHD.Relapse
A total of 5 patients relapsed following HSCT,
including 3 patients (27%; 95% CI, 9%-57%) who
relapsed after autologous HSCT and 2 patients (9%;
95% CI, 2%-30%) who relapsed after allogeneic
HSCT. Median time to relapse was 15.3 months
(range: 4.4-42.7 months) and 13.5 months (range:
7.3-19.6 months) following autologous and allogeneic
HSCT, respectively. Both patients with positive RT-
PCR for the PML-RARa fusion transcripts prior to
HSCT were in long-term molecular remission (second
CR duration 14 or more months longer than first CR)
post-HSCT (1 autologous and 1 allogeneic) at last
follow-up.
Of note, all 3 patients who relapsed after autolo-
gous HSCT had a negative RT-PCR for the PML-
RARa fusion transcript prior to HSCT and 2 had
a RT-PCR negative autograft product (1 was not re-
ported). Of these 3 patients, 1 died from progressive
APL 40 days after relapse (1323 days post-HSCT),
and 2 received second transplants from allogeneic sour-
ces. One of the second transplant patients died follow-
ing an unrelated donor transplant from a disseminated
adenoviral infection and the other survived in long-
term molecular remission after a matched-sibling
cord blood transplant (previously reported) [17].
The 2 relapses that occurred after allogeneic
HSCT both occurred in recipients of MRD grafts, in
whom no aGVHD or cGVHD occurred. Both patients
received second transplants. One patient died of inva-
sive aspergillosis following a second transplant from
the same MRD, and 1 patient survived in long-term
molecular remission after a paternal haploidentical
transplant (previously reported) [17].
Survival
As shown in Figure 1, for the 32 patients originally
treated on the ECOG E2491 or CALGB C9710 trials
who underwent HSCT for treatment of relapsed or
refractory APL, the 5-year EFS was 73% (95% CI,
43%-91%) with autologous HSCT, and 71% (95%
CI, 50%-86%) with allogeneic HSCT. One patient in
each group was successfully rescued with second
HSCT following relapse after first HSCT; therefore,
the 5-year OS was 82% (95% CI, 51%-96%) for autol-
ogous HSCT and 76% (95% CI, 55%-90%) for alloge-
neic HSCT. There was no significant difference between
autologous or allogeneic HSCT for EFS (P5 .81) or OS
(P5 1). Statistical analysis did not show any factors sig-
nificantly associated with an impact upon EFS or OS.
Excluding the 4 patients who died of TRM, the median
duration from HSCT to relapse or last follow-up was
43 months (range: 4-134 months) and 56 months (range:
7-139 months) for autologous and allogeneic HSCT,
respectively. The median performance score among
the survivors was 100% (range: 80%-100%).
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This is the largest study reported to date on the
outcome of children with relapsed or refractory APL.
All patients were able to ultimately achieve morpho-
logic remission with various salvage regimens and
proceed to consolidative HSCT, although 2 patients
entered HSCT positive for the PML-RARa fusion
transcript. Outcomes following any form of HSCT
were excellent, with a combined 5-year EFS of 72%
and OS of 78%.
In the 11 children with relapsed or refractory APL
(6 in molecular remission, 1 with molecular evidence
of disease, and 4 unknown molecular status) undergo-
ing autologous HSCT, we found a 5-year EFS of 73%.
Reports of autologous HSCT for APL in adults have
included from 10 to 50 patients each, and have demon-
strated an EFS ranging from 51%-90% [10-12,23].
Molecular status has not always been known prior to
autologous HSCT, although de Botton et al. [10] dem-
onstrated that 7-year EFS is superior for those patients
in molecular remission at time of HSCT, compared to
unknown molecular status (77% versus 50%; P5 .07).
In the 21 children with relapsed or refractory APL
undergoing allogeneic HSCT, we found a 5-year EFS
of 71%. Roman et al. [11] reported a group of 10 pa-
tients (including 1 child) undergoing allogeneic
HSCT with an EFS of 90%. The only patient that re-
lapsed was not in remission at the time of HSCT [11].
Larger reports of allogeneic HSCT for APL in adults
have included from 17 to 137 patients each, and have
demonstrated an EFS ranging from 46% to 59%
[10,12,15]. The only report of allogeneic HSCT for
APL in a solely pediatric population demonstrated
a 5-year OS of 73% in a group of 11 patients (8 with
cytogenetic confirmation) [16].
For most patients with leukemia, the primary
reason for transplant failure is relapse. In children
with AML in second complete remission, the relapse
Figure 1. Event-free survival following HSCT for childhood acute
promyelocytic leukemiaincidence following autologous HSCT ranges from
52% to 54% [24,25], whereas the relapse incidence fol-
lowing allogeneic HSCT ranges from 33% to 42%
[24,26]. In our cohort, patients undergoing autologous
and allogeneic HSCT demonstrated a relapse inci-
dence of 27% and 10%, respectively. Unfortunately,
we were not able to confirm the PML-RARa status of
all autograft products in this cohort. Meloni et al.
[14] confirmed the importance of a negative RT-PCR
for the t(15;17) prior to autologous HSCT in their
group of 15 patients (including 2 children). In that se-
ries, all 7 patients with positive RT-PCR in their pre-
transplant bone marrow aspirate relapsed following
HSCT, whereas 6 of 8 patients with negative RT-
PCR experienced sustained remission [14]. Clearly,
the ability to confirm RT-PCR negativity in both the
patient and the autograft product prior to infusion
may play a significant role in the successful selection
of patients most likely to benefit from autologous trans-
plant. Of note, whereas prior reports suggest that the
median time to relapse following autologous HSCT
is 5 to 8 months [13,21], 2 of the 3 relapses seen follow-
ing autologous HSCT in this cohort occurred over 1
year post-HSCT, suggesting that PCR-based screen-
ing of either peripheral blood or bone marrow for re-
lapse should be continued on a regular basis for at
least 2 years following autologous HSCT.
In the allogeneic setting, the only patients experi-
encing a relapse in this cohort underwent fully matched
sibling donor HSCT and did not manifest any evidence
of GVHD. We postulate that the low incidence of re-
lapse after allogeneic HSCT may be because of a high
susceptibility of APL to a graft-versus-leukemia (GVL)
effect. It has been shown in vitro that the PML-RARa
fusion protein contains a novel antigenic site recogniz-
able by CD41 lymphocytes in an HLA-restricted con-
text on antigen-presenting cells [27]. Lo-Coco et al.
[15] reported 2 patients with RT-PCR-positive testing
for disease postallogeneic HSCT, both of whom con-
verted to negative following withdrawal of immuno-
suppression, which provides evidence for an in vivo
GVL effect. In addition, successful treatment of persis-
tent molecular disease following MRD-HSCT with
donor lymphocytes infusions has been reported [28].
Other groups have reported low relapse incidences of
4% to 17% following allogeneic HSCT for APL [10-
12,15], providing further support for a stronger GVL
effect against residual APL compared to nonpromyelo-
cytic AML.
In this cohort, the biggest impediment to successful
outcome after allogeneic HSCT was a TRM of 19%.
Possibly because of low subject numbers, we were not
able to identify any predictors of TRM in patients
with relapsed or refractory APL. One contributor
to TRM after HSCT may be the intensity of the con-
ditioning regimen. In patients with high-risk AML,
Mengarelli et al. [15] reported no benefit of the
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standard regimen of TBI plus cyclophosphamide or
busulfan plus cyclophosphamide. In adults with APL
undergoing allogeneic HSCT, several groups have
shown that TBI-based conditioning is not superior to
busulfan-based conditioning [10,12]. Given the low re-
lapse rate seen in this cohort, and in other reports of
HSCT for relapsed or refractory APL, it appears likely
that intensified conditioning regimens will not be
found to be superior to standard regimens, especially
in the setting of mismatched and/or unrelated donor
transplants, where the GVL effect is expected to be
strongest.
Another variable that might impact TRM is the
type of secondary chemotherapy regimen used to
achieve remission prior to HSCT. Because of the
wide variety of regimens utilized in this cohort, no reg-
imen could be conclusively linked to an impact on
HSCT outcome. However, the importance of the pre-
transplant salvage regimen has been highlighted by the
case of gemtuzumab ozogamicin (GO), a monoclonal
antibody (mAb) against CD33, which has been shown
to be highly effective in relapsed APL [15]. As many
as 64% of patients that receive GO within 3.5 months
prior to HSCT ultimately develop evidence of sinusoi-
dal obstruction syndrome following transplant [29]. In
patients with APL, several groups have shown a high
incidence of TRM following intensive cytotoxic
chemotherapy regimens prior to allogeneic HSCT
[10,23]. As demonstrated by 1 patient in this cohort,
successful outcomes have been reported following
allogeneic HSCT despite lack of molecular remission
[10,11,15]. Some salvage regimens for APL utilize dif-
ferentiating agents (such as ATRA or ATO) that lack
significant cytotoxicity. Use of these agents in place
of conventional chemotherapy may represent a less
aggressive method by which to achieve morphologic
remission prior to HSCT that could potentially trans-
late into decreased post-HSCT TRM.
In addition to low patient numbers, the other ma-
jor limitation of this study is the retrospective nature,
in which we attempt to analyze the outcomes of trans-
plants done at different centers, utilizing multiple dif-
ferent salvage regimens, donor types, conditioning
regimens, and GVHD prophylaxis strategies. Clearly,
the optimal method to analyze outcomes for patients
with relapsed or refractory APL treated by HSCT
would be in the context of a standardized prospective
clinical trial in which interinstitutional variances could
be minimized.
In summary, this study provides further evidence
that for children with relapsed or refractory APL,
autologous HSCT can be successfully performed for
patients in remission. Other reports suggest that that
molecular remission of the patient and an autologous
stem cell product that is PCR negative for disease
significantly decrease relapse incidence following au-tologous transplantation [10,14]. If molecular remis-
sion is not able to be achieved, allogeneic HSCT can
be curative for many children. Few patients experience
relapse of APL following allogeneic HSCT, possibly
because of a strong GVL effect against residual dis-
ease. However, further improvements in supportive
care are needed to minimize the impact of TRM in
the allogeneic setting and thereby improve the overall
survival of children with relapsed or refractory APL.
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